/C O R R E C T I O N -- Schering-Plough Corporation/

In the news release, FDA Advisory Committee Votes in Favor of SAPHRIS(R)
(asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia, issued
30-Jul-2009 by Schering-Plough Corporation over PR Newswire, the first
paragraph, first sentence, should read "in favor of use" rather than "in favor
of youth" as incorrectly transmitted by PR Newswire. The complete, corrected
release follows:
FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute
Bipolar I Disorder and Acute Schizophrenia

KENILWORTH, N.J., July 30 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today announced that the U.S. Food and Drug
Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted
unanimously in favor of SAPHRIS(R) (asenapine) sublingual tablets as effective
and safe for the acute treatment of manic or mixed episodes associated with
bipolar I disorder in adults and in favor of use in acute treatment of
schizophrenia in adults. If approved by FDA, SAPHRIS would be the first
psychotropic drug to be approved initially for both of these indications.

"We are very pleased with the outcome of today's advisory committee meeting
and appreciate the panel's careful consideration of the efficacy and safety
data for SAPHRIS," said Thomas P. Koestler, Ph.D., executive vice president
and president, Schering-Plough Research Institute. "In clinical studies,
SAPHRIS has demonstrated efficacy combined with an attractive metabolic safety
profile. SAPHRIS has the potential to address a significant unmet need for
patients with schizophrenia and bipolar I disorder, including patients
starting treatment and those who need alternative treatment options when
switching or re-initiating therapy. We will continue to work with FDA to
bring SAPHRIS to the U.S. market as soon as possible so that patients can
benefit from this new medication."

While the FDA is not bound by the committee's recommendations, the agency
carefully considers them before making a final decision on approval. After
reviewing the SAPHRIS data, the committee voted in favor of SAPHRIS as
effective (by counts of 12/0/0 and 10/2/0, yes/no/abstain) and safe (12/0/0
and 10/0/2) for the bipolar I disorder and schizophrenia indications,
respectively. In addition, the committee voted on the overall balance of
safety and efficacy by counts of 12/0/0 and 9/1/2 for the bipolar I disorder
and schizophrenia indications, respectively.

The New Drug Application (NDA) for SAPHRIS includes efficacy data from a
clinical trial program involving more than 3,000 patients in schizophrenia and
bipolar mania trials, and is supported by safety data in 4,500 patients, with
some treated for more than two years.

In Europe, a Marketing Authorization Application (MAA) for asenapine, under
the brand name SYCREST(R), is currently under review by the European Medicines
Agency (EMEA) for the treatment of schizophrenia and manic episodes associated
with bipolar I disorder. The application will follow the Centralized
Procedure.

Schering-Plough acquired asenapine in November 2007 through its acquisition of
Organon BioSciences, which developed the product.

About Schizophrenia

Schizophrenia is a chronic, disabling brain disorder that is characterized by
hallucinations, delusions and disordered thinking. The condition affects
about 24 million people worldwide (or seven in every 1,000 adults in the
population), including more than two million people in the United States and
more than four million people in Europe. Although there are a number of
medications available for patients, treatment success for any antipsychotic
agent can be unpredictable because patients often respond differently to
various medications. Among patients with schizophrenia who are being treated
with antipsychotics, nearly three in four patients discontinue therapy within
18 months due to either poor tolerability or incomplete efficacy. Metabolic
safety, including weight gain, elevation of lipid levels (dyslipidemia) and
glucose dysregulation, is an important consideration with any antipsychotic
treatment. Patients often need to switch treatments in order for physicians
to balance effective treatment with the long-term safety of their patients.

About Bipolar I Disorder

Bipolar I disorder (also known as manic depression) is a chronic, episodic
illness characterized by mania (episodes of elevated moods, extreme
irritability, decreased sleep and increased energy), depression (overwhelming
feelings of sadness, suicidal thoughts), or a combination of both. It is the
sixth leading cause of disability in the world, affecting approximately 1 to 5
percent of adults, including 10 million Americans. About half of the patients
with bipolar disorder who recover in response to treatment experience
recurrence two years later. Patients may experience a high rate of failure
due to lack of efficacy or side effects, including metabolic side effects.
Poor tolerability frequently leads to treatment discontinuation even when the
treatment is providing some benefit. To help manage this challenge, patients
often receive multiple medications or need to switch treatments.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care
company. Through its own biopharmaceutical research and collaborations with
partners, Schering-Plough creates therapies that help save and improve lives
around the world. The company applies its research-and-development platform
to human prescription, animal health and consumer health care products.
Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors,
patients, customers and other stakeholders served by its colleagues around the
world. The company is based in Kenilworth, N.J., and its Web site is
www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release
includes certain "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
relating to the clinical development of, the commercial plans for and the
potential market for SAPHRIS/SYCREST. Forward-looking statements relate to
expectations or forecasts of future events. Schering-Plough does not assume
the obligation to update any forward-looking statement. Many factors could
cause actual results to differ materially from Schering-Plough's
forward-looking statements, including uncertainties in the regulatory process,
among other uncertainties. For further details about these and other factors
that may impact the forward-looking statements, see Schering-Plough's
Securities and Exchange Commission filings, including Part II, Item 1A. "Risk
Factors" in the Company's second quarter 2009 10-Q, filed July 24, 2009.

SOURCE Schering-Plough Corporation

Media, Robert Consalvo, +1-908-298-7409, office, or +1-908-295-0928, mobile,
or Investors, Janet Barth, +1-908-298-7436, office, or Joe Romanelli,
+1-908-298-7436, office, all for Schering-Plough Corporation